Clinical Trials Browser

Recruiting × tislelizumab × Gynecologic × Clear all

NCT06063018 2023-10-02

RC48 Combined With Tislelizumab for Second-line Treatment of HER2 Expression in Recurrent Cervical Cancer

Phase 2 Recruiting

Cervical Cancer Recurrent

NCT05511623 2023-09-11

Tislelizumab Combined With Concurrent Chemoradiotherapy as First-line Treatment for Stage IIIC2 Cervical Cancer

Phase 2 Recruiting

Uterine Cervical Neoplasms